Multiple Myeloma CAR T-Cell Therapy: What Patients Face in 2026

Introduction: A Breakthrough Treatment With a Hidden Obstacle Course

CAR T-cell therapy is one of the most significant advances in the treatment of relapsed/refractory multiple myeloma (RRMM). Long-term data released in 2026 suggest that for a meaningful subset of patients, a single infusion can produce durable remission without ongoing treatment. For a disease long defined by repeated relapse, that is a notable shift.

Most public information about myeloma CAR-T falls into two groups. Investor-facing press releases from Legend Biotech, Johnson & Johnson, and Bristol Myers Squibb announce trial wins. Clinician-facing trial summaries describe response rates and toxicity grades. Very little describes what patients and families go through between the decision to pursue CAR-T and the day of infusion.

This article brings both sides together. It covers the clinical efficacy and safety data, the leukapheresis waitlist and manufacturing process, side-effect management (including the two-month driving ban), the full cost of an episode of care, and where the field is heading in 2026 and beyond. It is written for patients, caregivers, and anyone researching multiple myeloma CAR T-cell therapy.

What Multiple Myeloma CAR T-Cell Therapy Actually Is

CAR T-cell therapy is often called a “living drug.” The process has four main steps:

1. Collection. The patient’s own T-cells, a type of immune cell, are collected from the blood.
2. Engineering. In a lab, the cells are genetically modified to carry a chimeric antigen receptor (CAR) that recognizes a specific target on myeloma cells.
3. Expansion. The engineered cells are grown into the millions.
4. Reinfusion. The cells are returned to the patient, where they seek out and attack the cancer.

This approach is different from the other main treatment options:

• Autologous stem cell transplant uses high-dose chemotherapy followed by the patient’s own stem cells to rebuild the bone marrow.
• Standard regimens combine proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 antibodies, usually given continuously.
• Bispecific antibodies are off-the-shelf drugs that connect the patient’s existing T-cells to myeloma cells. They require repeated dosing but no cell manufacturing.

The Two FDA-Approved Products: Ide-Cel and Cilta-Cel

Two CAR-T products are currently approved for myeloma:

• Idecabtagene vicleucel (ide-cel, Abecma), approved in March 2021
• Ciltacabtagene autoleucel (cilta-cel, Carvykti), approved in February 2022

Both target B-cell maturation antigen (BCMA), a protein found at high levels on myeloma cells and at limited levels on most healthy tissue. This makes BCMA the main target for current myeloma CAR-T. In April 2024, the FDA approved both products for earlier lines of treatment, which greatly expanded the number of eligible patients.

Who Qualifies for CAR-T in 2026

Under current labeling:

• Carvykti is approved after just one prior line of therapy that included a PI and an IMiD.
• Abecma is approved after at least two prior lines that included a PI, an IMiD, and an anti-CD38 antibody.

Before the 2024 expansion, patients generally needed four or more prior lines before they could receive CAR-T. Many patients now qualify years earlier in their disease, when they are typically healthier and their immune systems are stronger.

Meeting the label criteria is not the only requirement. In practice, treatment centers also look at:

• Organ function, especially heart, lung, kidney, and liver health
• Performance status, meaning the patient’s overall fitness and ability to carry out daily activities
• T-cell health, because heavy prior treatment can leave too few healthy T-cells to collect and manufacture successfully

Eligibility is only the first hurdle. Access, covered below, is a separate barrier and often the harder one.

The Clinical Evidence: How Well Does It Actually Work?

This section summarizes the main trial results and explains what they mean for patients weighing their options.

CARTITUDE-4: Cilta-Cel vs. Standard Therapy

CARTITUDE-4 compared cilta-cel with standard regimens in patients who had received 1-3 prior lines of therapy. The overall response rate was 85% with cilta-cel versus 67% with standard therapy. Cilta-cel also reduced the risk of disease progression or death by 59%.

For someone at first or second relapse, these results mean CAR-T is no longer only a last resort. Given earlier, it is more likely to produce a response, and that response is more likely to last than one from a continuous drug regimen.

Five-Year Follow-Up: How Durable Are Remissions?

The most notable 2026 data concern how long remissions last.

CARTITUDE-2 Cohort A (presented in September 2026 at the International Myeloma Society meeting) followed early-relapse patients with 1-3 prior lines:

• 50% were alive and progression-free five years after a single infusion, with no maintenance therapy
• Five-year overall survival: 69.2%
• Median progression-free survival: 60.5 months

CARTITUDE-1 followed heavily pretreated patients with a median of six prior lines:

• 33% achieved five or more years of progression-free survival after a single infusion, with no maintenance or later anti-myeloma treatment
• Median overall survival: 60.7 months

These results support the idea of treatment-free remission. For some patients, one infusion may provide lasting disease control rather than serving as a bridge to the next therapy. These are trial populations, however, and individual outcomes vary widely. Broader patient-facing sources in 2026 report five-year survival for multiple myeloma overall climbing toward 62-65%. That figure covers the whole disease population and is not specific to CAR-T.

Ide-Cel vs. Cilta-Cel: How They Are Actually Positioned

Cilta-cel’s earlier-line approval and generally higher response rates have made it the preferred choice for many patients at first relapse. Ide-cel remains an important option. Clinicians may choose it based on a patient’s specific risks, toxicity concerns, or treatment history.

In practice, the choice often depends on center experience, slot availability, and patient-specific factors, not on patient preference alone. A patient may receive whichever product their center can schedule first.

Sequencing guidance from the IMWG and European Myeloma Network increasingly frames the 2026 decision as “CAR-T or bispecific first,” rather than CAR-T versus standard care.

The Part No One Talks About: The Wait Before Treatment

Trial data assume a patient receives the infusion. In practice, getting to infusion can be the hardest part of the process.

The Leukapheresis Waitlist Crisis

A survey of CAR-T physician leaders at 17 U.S. treatment centers found:

• A median of only 1 CAR-T slot allocated per month per center
• About 20 patients on each center’s waitlist
• A median 6-month wait before leukapheresis (cell collection) even begins

Respondents estimated that 25% of waitlisted patients died or moved to hospice while waiting.

Several factors cause this shortage:

• Limited manufacturing capacity, since each product is custom-made for one patient
• Specialized center requirements, including trained staff, intensive care backup, and certified facilities
• Rising demand after the label expansions, which has outpaced supply

The constraints also affect health systems. An analysis published in AJMC found that, at current pricing, only 43% of eligible RRMM patients could be treated within five years before exceeding standard budget-impact thresholds.

Manufacturing Time and the Bridging Therapy Gamble

Once cells are collected, the “vein-to-vein” time (from collection to infusion) typically runs 3-6 weeks and sometimes up to 8 weeks.

During this time, many patients need bridging therapy to keep aggressive disease under control. Bridging involves a trade-off. Too little treatment risks the disease progressing. Too much can weaken the patient or cause complications before infusion.

A 2026 EBMT survey found that:

• Most centers use 1-2 months of bridging therapy
• 81% start bridging within one week of apheresis
• More than 95% proceed to infusion even if the disease progresses during bridging

Manufacturing speed varies. The investigational product PHE885 reported an average of 16 days from apheresis to lymphodepletion. Some international centers report turnaround times of 24-36 hours, which suggests where the field may be heading.

Manufacturing does not always succeed on the first attempt. In real-world ide-cel data, about 6% of patients needed a second leukapheresis and 6% received an out-of-specification product. This adds uncertainty to an already stressful wait.

What to Expect During and After Infusion

Before infusion, patients usually receive lymphodepleting chemotherapy to prepare the body for the engineered cells. After infusion, they are closely monitored, often in the hospital at first. Major centers such as MD Anderson advise that patients and caregivers remain near the treatment center for roughly the first 30 days after infusion.

A dedicated caregiver is required. In practice, this can mean:

• Taking extended time off work
• Traveling to a center that may be far from home
• Arranging temporary housing nearby
• Being available around the clock to watch for warning signs

Cytokine Release Syndrome and ICANS

Cytokine release syndrome (CRS) is an inflammatory reaction that occurs as CAR T-cells activate. It often causes fever and low blood pressure.

• CARTITUDE-4: 78% of patients experienced CRS; only 3% had Grade 3-4 (severe) cases
• CARTITUDE-1: 95% experienced CRS; 4% had Grade 3-4 cases

ICANS (immune effector cell-associated neurotoxicity syndrome) ranges from mild confusion or trouble finding words to, rarely, seizures or encephalopathy. In trial data, ICANS resolved in 83% of affected patients, with a median resolution time of 3 days. Delayed or prolonged cases do occur.

Patients are monitored closely because these reactions usually appear early and respond well to treatment when caught quickly. Most cases are manageable, but the risks are real.

The Two-Month Driving Ban and Its Real-Life Impact

Because of the risk of delayed neurotoxicity, the FDA label prohibits driving or operating heavy machinery for two months after infusion.

Clinical summaries rarely discuss what this means day to day. Patients lose a significant measure of independence. Caregivers must handle all transportation, including frequent follow-up appointments. Work schedules, school pickups, and childcare all need to be rearranged.

Families can prepare by:

• Arranging a rotation of drivers among family and friends
• Talking with employers early about leave or flexible schedules
• Looking into patient transportation programs offered by hospitals or advocacy groups
• Planning for rural access gaps, since patients who live far from a center may face long trips with limited public transit

Beyond CRS and ICANS: The Toxicities That Linger

Clinicians are paying more attention to complications that last beyond the first weeks:

• Prolonged cytopenias: low blood cell counts that can last for weeks or months
• Hypogammaglobulinemia: low antibody levels, sometimes requiring immunoglobulin replacement
• Infections: increased risk while the immune system recovers

A rarer but serious complication is immune effector cell-associated HLH-like syndrome (IEC-HS), a severe inflammatory condition that needs prompt recognition and treatment.

Recovery is not a single event. It is a months-long process of immune recovery, regular blood tests, infection prevention, and follow-up care.

Understanding the True Cost of the Care Journey

The list price of the CAR-T product is only one part of the total cost. The full episode of care includes:

• Leukapheresis
• Bridging therapy
• Lymphodepleting chemotherapy
• The inpatient stay for infusion and monitoring
• Management of CRS and ICANS, sometimes including intensive care
• Follow-up visits over many months
• Treatment of lingering toxicities, such as immunoglobulin replacement and infection management

An independent cost-effectiveness analysis from ICER has assessed the value of CAR-T compared with standard care. The overall picture is that of a resource-intensive treatment that may still offer high value for eligible patients, particularly given the durable remissions now being reported.

At the system level, these costs limit how many eligible patients health systems can treat within a given period. This adds to the access barriers described above.

Patients should meet early with financial counselors at their treatment center and contact their insurer before treatment begins. Prior authorizations, coverage of travel and housing, and out-of-pocket estimates all take time to sort out, and that work is part of the burden before treatment.

CAR-T or Something Else? Navigating the 2026 Decision Tree

At relapse, patients generally consider four options:

1. CAR T-cell therapy
2. Bispecific antibodies
3. Stem cell transplant (for selected patients)
4. A clinical trial

Bispecific antibodies, including teclistamab (Tecvayli), talquetamab (Talvey), and elranatamab (Elrexfio), are the main alternative to CAR-T that does not involve cell therapy. Their biggest advantage is that they are available off the shelf: there is no collection, no manufacturing wait, and no waitlist. The trade-off is ongoing dosing rather than a single infusion.

Following the CARTITUDE-4 and MajesTEC-3 trials, both cilta-cel and teclistamab (combined with daratumumab) are now FDA-approved at first relapse. With both a cell therapy and a bispecific now available this early in the disease course, 2026 guidance increasingly frames the choice as “CAR-T or bispecific first.”

Factors beyond efficacy that shape the decision include:

• Slot availability and the expected wait
• Patient fitness and disease pace (fast-moving disease may not be able to wait for manufacturing)
• Center experience with each type of therapy
• Patient preference between one infusion after an initial delay and ongoing bispecific treatment that can start right away

What Happens If CAR-T Stops Working: Relapse and Next-Generation Options

When myeloma returns after CAR-T, a common cause is antigen loss, especially BCMA escape. In this case, the myeloma cells reduce or lose the BCMA target, so the engineered T-cells can no longer find them. This is why next-generation approaches matter to patients and not only to investors.

The Next Wave of BCMA-Targeted and Dual-Target CAR-T

Anito-cel (anitocabtagene autoleucel), developed by Arcellx and now owned by Gilead after its acquisition of the company, had its BLA accepted by the FDA in February 2026 for fourth-line RRMM. The FDA decision date is December 23, 2026.

Dual-antigen, “escape-resistant” designs are also in development. These include Janssen’s JNJ-79635322, which targets both GPRC5D and BCMA, and BMS-986453. By targeting two proteins at once, they aim to make it much harder for myeloma to escape by losing a single target.

For patients, these products may become future options after a first CAR-T stops working.

Beyond BCMA: GPRC5D-Targeted Arlo-Cel

Bristol Myers Squibb’s arlo-cel (arlocabtagene autoleucel) would be the first myeloma CAR-T to target GPRC5D instead of BCMA. It met its primary endpoint in the pivotal QUINTESSENTIAL trial in quad-class-exposed RRMM, with a launch targeted for 2027.

A non-BCMA target is especially important for patients who have relapsed after BCMA-directed CAR-T or bispecific therapy. If BCMA is no longer present on the myeloma cells, a therapy aimed at a different target may still work.

Off-the-Shelf and In-Vivo Approaches: Solving the Wait Itself

Allogeneic (“off-the-shelf”) CAR-T uses donor-derived or engineered cells that are made in advance. This could remove the weeks-long manufacturing wait and possibly reduce the need for lymphodepleting chemotherapy. Programs in development include Poseida’s P-BCMA-ALLO1, among other iPSC-derived and allogeneic platforms being explored across the field.

As of 2026, none of these allogeneic programs are approved. Allogeneic approaches in general have struggled to match the clinical results of approved autologous products.

In-vivo CAR-T takes a different approach: the patient’s T-cells are engineered inside the body, so no external manufacturing is needed. Kelonia Therapeutics’ KLN-1010, an in vivo BCMA CAR-T, received FDA IND clearance in January 2026 after first-in-human data were presented at ASH 2025. If successful, this approach could eliminate the manufacturing wait entirely.

Some patients are also looking at international options. Centers in China report significantly lower total costs and, in some cases, manufacturing turnaround of 24-36 hours. Patients considering this route should look carefully at regulatory differences, follow-up care, and how treatment will be coordinated with their home oncology team.

Practical Guidance for Patients and Caregivers Starting This Journey

• Ask early about the waitlist. As soon as CAR-T is under consideration, ask the center about waitlist position, the expected timeline, and the bridging therapy plan.
• Plan caregiver logistics in advance. Arrange housing near the center, prepare for the roughly 30-day proximity requirement, and set up transportation for the two-month driving restriction before infusion.
• Start financial counseling right away. Given the many layers of cost, involve center financial counselors and insurers from the beginning.
• Ask about clinical trials. If standard CAR-T access is delayed, or if a prior CAR-T has failed, ask about eligibility for studies of anito-cel, arlo-cel, dual-target, or in-vivo products.
• Get a second opinion. Slot availability and experience vary between centers, so a consultation at a high-volume CAR-T center can change both timing and options.

Conclusion: A Genuinely Transformative Therapy With a Human Cost

Five-year progression-free survival after a single infusion in a meaningful share of patients is a real and unprecedented advance in RRMM care. For some patients, the goal is now lasting treatment-free remission rather than simply delaying the next relapse.

That promise depends on reaching infusion. Waitlists, manufacturing delays, bridging therapy risks, toxicity management, and cost all affect whether and when a patient receives treatment. Patients and caregivers who understand both the benefits and these obstacles are better able to advocate for themselves.

The field is moving quickly. Next-generation BCMA products, GPRC5D targeting, and off-the-shelf and in-vivo approaches may ease access barriers in the coming years. Patients making decisions today, however, must work within the current system.

Next Steps: Talk to Your Care Team Early

Patients who have recently relapsed or are considering CAR-T should raise the topic with their oncology team as early as possible, because the waitlist may start long before treatment is needed. This guide can serve as a reference when comparing CAR-T, bispecific antibodies, and clinical trial options with the care team. It may also help to share it with the caregivers and family members who will manage logistics during treatment, since much of the process depends on their support.

Individual eligibility, timing, and product choice depend on medical factors that no general resource can fully address. Personalized guidance from a qualified hematology-oncology specialist, ideally at an experienced CAR-T center, remains the most important next step.